SDA-2026-04-04-gap-20260404-microglial-priming-early-ad

Based on the provided literature, here are 7 novel therapeutic hypotheses for targeting microglial priming in early Alzheimer's disease: ## 1. Circadian-Metabolic Microglial Reprogramming **Description:** Restoring circadian rhythms through targeted light therapy and chronotherapy could reprogram primed microglia by resetting their metabolic clock, shifting them from pro-inflammatory glycolytic metabolism back to homeostatic oxidative phosphorylation. This approach would target the intersection of sleep disruption, metabolic dysfunction, and neuroinflammation in prodromal AD. **Target gene/protein:** CLOCK/BMAL1 circadian transcription factors, PER2 **Supporting evidence:** PMID 41256678 demonstrates that dim light at night impacts circadian rhythms and AD-like neuroinflammation, suggesting circadian disruption directly affects microglial activation states. **Confidence:** 0.75 ## 2. Astrocyte-Mediated Microglial Memory Erasure **Description:** Enhancing astrocyte priming selectively could create a therapeutic window where astrocytes promote microglial Aβ clearance while simultaneously releasing factors that "erase" pathological microglial memory. This dual approach would leverage the beneficial aspects of astrocyte activation while reversing harmful microglial priming. **Target gene/protein:** GFAP, S100B, and astrocyte-specific complement factors **Supporting evidence:** PMID 40813385 shows that astrocyte priming enhances microglial Aβ clearance, and this is compromised by APOE4, suggesting astrocyte-microglia crosstalk is a viable therapeutic target. **Confidence:** 0.70 ## 3. Peripheral-Central Immune Decoupling Therapy **Description:** Developing treatments that selectively block the transmission of peripheral inflammatory signals to brain microglia while preserving beneficial peripheral immune responses could prevent microglial priming without compromising systemic immunity. This would involve targeting specific transport mechanisms at the blood-brain barrier. **Target gene/protein:** TREM2, complement cascade components, blood-brain barrier transporters **Supporting evidence:** PMID 27555812 discusses the tight interaction between immune system and brain in AD pathogenesis, suggesting peripheral-central immune communication as a therapeutic target. **Confidence:** 0.65 ## 4. Gut-Brain Axis M-Cell Modulation **Description:** Inhibiting or modulating microfold (M) cells in Peyer's patches could prevent gut-derived inflammatory signals and bacterial products from reaching the brain and priming microglia. This approach would target the earliest stages of peripheral-to-central inflammation transmission via the gut-brain axis. **Target gene/protein:** GP2 (glycoprotein 2), SPIB transcription factor, intestinal alkaline phosphatase **Supporting evidence:** PMID 38012646 demonstrates that inhibition of microfold cells ameliorates early pathological phenotypes by modulating gut-brain communication in AD models. **Confidence:** 0.68 ## 5. APOE4-Specific Microglial Metabolic Rescue **Description:** Developing APOE4-specific interventions that restore normal microglial lipid metabolism and cholesterol homeostasis could prevent the enhanced inflammatory priming seen in APOE4 carriers. This would involve targeting the specific metabolic pathways disrupted by APOE4 in microglia. **Target gene/protein:** APOE, ABCA1, LDLR, cholesterol synthesis enzymes **Supporting evidence:** PMID 40813385 shows that APOE4 compromises astrocyte priming effects on microglial clearance, indicating APOE4-specific pathological mechanisms in microglial function. **Confidence:** 0.72 ## 6. DAMP-Scavenging Microglial Reset **Description:** Engineering therapeutic nanoparticles or enhancing endogenous systems to specifically scavenge damage-associated molecular patterns (DAMPs) in the brain microenvironment could prevent the chronic activation signals that maintain microglial priming. This would essentially "clean the slate" for microglial reprogramming. **Target gene/protein:** HMGB1, S100 proteins, extracellular ATP, purinergic receptors **Supporting evidence:** PMID 27555812 discusses DAMPs as key mediators of microglial activation in AD, suggesting their removal could reverse priming. **Confidence:** 0.63 ## 7. Temporal Microglial State Switching **Description:** Developing interventions that can temporally control microglial activation states—promoting clearance functions during specific windows while suppressing inflammation during others—could optimize microglial responses throughout AD progression. This would involve programmable delivery systems or light-activated switches. **Target gene/protein:** Optogenetic constructs targeting microglial ion channels, temporal drug delivery systems **Supporting evidence:** The literature suggests microglial priming is a temporal process (PMID 27555812) and that timing of interventions matters for effectiveness, as shown by the astrocyte priming study (PMID 40813385). **Confidence:** 0.6 [...]